NAC for Attenuation of COVID-19 Symptomatology

N-acetylcysteine for Attenuation of COVID Symptomatology

The objective of this study is to determine whether oral NAC is effective at attenuating COVID-19 disease symptom severity and duration of symptoms.

STUDY DESIGN: Randomized double-blinded placebo-controlled trial

ELIGIBILITY

Inclusion criteria:

• age 18 years and older
• participants will need daily access to use of a smartphone for at least six weeks from time of enrollment
• Positive COVID-19 test within 10 days of date of enrollment
• not already hospitalized for treatment of COVID

Exclusion criteria:

• pregnant
• already hospitalized for treatment of COVID

PROTOCOL

• 50:50 randomization: half of participants will take NAC, half will take placebo
• Participants will take NAC/placebo following this outpatient protocol:
• 2400 mg x 1 PO then
• 1200 mg PO BID x 14 days
• Participants will complete an online symptom-tracker for six weeks (daily for three weeks, weekly for three weeks)

Inclusion Criteria:

• positive COVID test <= 7 days of enrollment

Exclusion Criteria:

• pregnant
• already hospitalized due to COVID